What The Study Did: This open-label randomized trial compares the effect of remdesivir (5 or 10 days) compared with standard care on clinical status 11 days after treatment initiation among patients with confirmed SARS-CoV-2 infection hospitalized with moderate pneumonia.
Authors: Diana M. Brainard, M.D., of Gilead Sciences in Foster City, California, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2020.16349)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.16349?guestAccessKey=82e07e86-0461-4065-b286-05aa2cec402a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082120
JAMA